Immunovant Valuation
| IMVT Stock | USD 18.79 1.23 6.14% |
At this time, the firm appears to be undervalued. Immunovant retains a regular Real Value of $26.33 per share. The prevalent price of the firm is $18.79. Our model calculates the value of Immunovant from evaluating the firm fundamentals such as Return On Asset of -0.45, shares owned by insiders of 58.07 %, and Return On Equity of -0.74 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Immunovant's valuation include:
Undervalued
Today
Please note that Immunovant's price fluctuation is not too volatile at this time. Calculation of the real value of Immunovant is based on 3 months time horizon. Increasing Immunovant's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Immunovant's intrinsic value may or may not be the same as its current market price of 18.79, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.79 | Real 26.33 | Target 50.25 | Hype 18.39 | Naive 18.58 |
The intrinsic value of Immunovant's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunovant's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunovant helps investors to forecast how Immunovant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunovant more accurately as focusing exclusively on Immunovant's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immunovant's intrinsic value based on its ongoing forecasts of Immunovant's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immunovant's closest peers.
Immunovant Cash |
|
Immunovant Valuation Trend
Immunovant's real value is important for investors to make better decisions and a more accurate overall view of Immunovant's financial worth over time. Using both Immunovant's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Immunovant Total Value Analysis
Immunovant is currently anticipated to have valuation of 3.02 B with market capitalization of 3.4 B, debt of 138 K, and cash on hands of 427.2 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immunovant fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.02 B | 3.4 B | 138 K | 427.2 M |
Immunovant Asset Utilization
One of the ways to look at asset utilization of Immunovant is to check how much profit was generated for every dollar of assets it reports. Immunovant retains a negative application of resources of -0.45 (percent), losing $0.004473 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Immunovant shows how discouraging it operates for each dollar spent on its resources.Immunovant Ownership Allocation
Immunovant has a total of 169.86 Million outstanding shares. Immunovant secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Also note that almost nine million five hundred ninety-seven thousand one hundred fourty-six invesors are currently shorting Immunovant expressing very little confidence in its future performance.Immunovant Profitability Analysis
Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0.About Immunovant Valuation
The stock valuation mechanism determines Immunovant's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Immunovant based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Immunovant. We calculate exposure to Immunovant's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunovant's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -207.9 K | -218.3 K |
Immunovant Growth Indicators
Investing in growth stocks can be very risky. If the company such as Immunovant does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 138.1 M |
Immunovant Current Valuation Indicators
Immunovant's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Immunovant's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immunovant, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immunovant's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immunovant's worth.Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.